EV / EBITDA společnosti Hancock Jaffe Laboratories Inc
Jaká je hodnota metriky EV / EBITDA společnosti Hancock Jaffe Laboratories Inc?
Hodnota metriky EV / EBITDA společnosti Hancock Jaffe Laboratories Inc je N/A
Jaká je definice metriky EV / EBITDA?
EV/EBITDA je podniková hodnota dělená EBITDA (zisk před odečtením úroků, daní, odpisů a amortizací). Měří nákladnost akcie a používá se k porovnání společností mezi sebou častěji než P/E ratio. Měří cenu, jakou investor zaplatí za pohyb hotovosti ve společnosti.
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
Čemu se věnuje společnost Hancock Jaffe Laboratories Inc?
Hancock Jaffe Laboratories specializes in developing and manufacturing bioprosthetic (tissue-based) medical devices to establish improved standards of care for treating cardiac and vascular diseases. HJLI currently has two lead product candidates: the VenoValveÒ, a porcine-based valve which is intended to be surgically implanted in the deep venous system of the leg to treat reflux associated with Chronic Venous Insufficiency, and the CoreoGraftÒ, a bovine tissue-based off-the-shelf conduit intended to be used for coronary artery bypass surgery.